Helping Israel
help the world
18n Ventures backs exceptional early-stage Israeli BioAI companies developing life-changing solutions at the intersection of artificial intelligence, technology, biology, and healthcare.
18n Ventures backs exceptional early-stage Israeli BioAI companies developing life-changing solutions at the intersection of artificial intelligence, technology, biology, and healthcare.
The name 18n reflects our belief that the future of healthcare lies at the intersection of biology and advanced technology.
18 represents Chai — life, health, and biology — while n represents technology, including AI and advanced computation.
Together, 18n represents the convergence of biology and technology — what we call BioAI — and the potential for exponential impact in healthcare.
Artificial intelligence, computational methods and engineering advances are converging with biological and clinical data to form BioAI.
The BioAI healthcare transformation is accelerating drug discovery, enabling earlier disease detection, improving clinical decision-making, and reshaping healthcare delivery.
Globally, BioAI companies are already generating significant impact and value. We believe this is only the beginning.
Source: Ultima Genomics, Boston Consulting Group, Artis Ventures, McKinsey, AD Little, Markets & Markets, JP Morgan, DEALFORMA
A complementary blend of investment and strategy acumen, entrepreneurial success, operational start-up experience, clinical and scientific knowledge, technology know-how and love of Israel. Partners have collaborated for many years.
Two investments are warehoused for the fund, providing immediate portfolio exposure from day one.
Deep connections across the Israeli BioAI ecosystem and access to a broad pipeline of promising early-stage companies.
Warehoused investments provide immediate portfolio exposure from day one.
Extensive experience evaluating and supporting early-stage healthcare companies across clinical, scientific, and technology dimensions.
Focused on platform-based companies addressing major healthcare challenges with durable, scalable solutions.
Strong US healthcare connections to help Israeli BioAI companies access global markets and accelerate commercial traction.
Investors and builders spanning investment strategy, entrepreneurship, clinical science, and deep technology — with years of collaboration.
18ⁿ Ventures partners with exceptional early-stage Israeli BioAI companies developing life-changing solutions at the intersection of AI, technology, biology, and healthcare.
If you would like to learn more or share an investment opportunity, please contact us.
